NYSE: JNJ | Healthcare / Drug Manufacturers / USA |
170.20 | -0.9100 | -0.53% | Vol 4.61M | 1Y Perf -1.16% |
Aug 8th, 2022 16:00 DELAYED |
BID | 170.00 | ASK | 170.90 | ||
Open | 171.30 | Previous Close | 171.11 | ||
Pre-Market | - | After-Market | 170.79 | ||
- - | 0.59 0.35% |
Target Price | 186.33 | Analyst Rating | Moderate Buy 2.06 | |
Potential % | 9.48 | Finscreener Ranking | ★ 39.18 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★ 45.96 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★ 53.23 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | ★★+ 43.34 | |
Price Range Ratio 52W % | 46.75 | Earnings Rating | Sell | |
Market Cap | 447.49B | Earnings Date | 19th Jul 2022 | |
Alpha | 0.00 | Standard Deviation | 0.05 | |
Beta | 0.63 |
Today's Price Range 169.44171.48 | 52W Range 155.72186.69 | 5 Year PE Ratio Range 18.70310.40 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -1.57% | ||
1 Month | -4.53% | ||
3 Months | -4.02% | ||
6 Months | -0.75% | ||
1 Year | -1.16% | ||
3 Years | 28.90% | ||
5 Years | 27.75% | ||
10 Years | 176.52% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 15.55 | |||
ROE last 12 Months | 27.93 | |||
ROA (5Y Avg) | 5.72 | |||
ROA last 12 Months | 11.18 | |||
ROC (5Y Avg) | 11.21 | |||
ROC last 12 Months | 19.19 | |||
Return on invested Capital Q | 4.77 | |||
Return on invested Capital Y | 4.51 | |||
Assets Turnover | 0.40 | |||
Receivables Turnover | 4.90 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
24.00 | ||||
6.28 | ||||
6.41 | ||||
20.40 | ||||
71.60 | ||||
8.72 | ||||
-100.95 | ||||
28.39 | ||||
471.76B | ||||
Forward PE | 16.24 | |||
PEG | 4.62 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.10 | ||||
1.40 | ||||
0.28 | ||||
0.44 | ||||
164.10 | ||||
Leverage Ratio | 2.40 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
68.00 | ||||
22.50 | ||||
30.10 | ||||
18.60 | ||||
18.87 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
71.57B | ||||
27.20 | ||||
4.58 | ||||
4.50 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.59 | ||||
4.52 | ||||
4.92 | ||||
5.56 | ||||
Payout ratio | 61.00 |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2022 | 2.57 | 2.59 | 0.78 |
Q01 2022 | 2.60 | 2.67 | 2.69 |
Q04 2021 | 2.12 | 2.13 | 0.47 |
Q03 2021 | 2.37 | 2.60 | 9.70 |
Q02 2021 | 2.28 | 2.48 | 8.77 |
Q01 2021 | 2.31 | 2.59 | 12.12 |
Q04 2020 | 1.81 | 1.86 | 2.76 |
Q03 2020 | 1.99 | 2.20 | 10.55 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
9/2022 QR | 2.56 | -1.92 | Negative |
12/2022 QR | 2.21 | -6.36 | Negative |
12/2022 FY | 10.05 | -1.47 | Negative |
12/2023 FY | 10.53 | -2.05 | Negative |
Next Report Date | - |
Estimated EPS Next Report | 2.57 |
Estimates Count | 7 |
EPS Growth Next 5 Years % | 5.20 |
Volume Overview | |
---|---|
Volume | 4.61M |
Shares Outstanding | 2.63M |
Shares Float | 2.63B |
Trades Count | 71.47K |
Dollar Volume | 785.95M |
Avg. Volume | 5.76M |
Avg. Weekly Volume | 5.29M |
Avg. Monthly Volume | 5.51M |
Avg. Quarterly Volume | 6.47M |
Johnson & Johnson (NYSE: JNJ) stock closed at 170.2 per share at the end of the most recent trading day (a -0.53% change compared to the prior day closing price) with a volume of 4.61M shares and market capitalization of 447.49B. Is a component of S&P 500, Dow Jones 30, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 136400 people. Johnson & Johnson CEO is Alex Gorsky.
The one-year performance of Johnson & Johnson stock is -1.16%, while year-to-date (YTD) performance is -0.51%. JNJ stock has a five-year performance of 27.75%. Its 52-week range is between 155.72 and 186.69, which gives JNJ stock a 52-week price range ratio of 46.75%
Johnson & Johnson currently has a PE ratio of 24.00, a price-to-book (PB) ratio of 6.28, a price-to-sale (PS) ratio of 6.41, a price to cashflow ratio of 20.40, a PEG ratio of 2.32, a ROA of 11.18%, a ROC of 19.19% and a ROE of 27.93%. The company’s profit margin is 18.87%, its EBITDA margin is 30.10%, and its revenue ttm is $71.57 Billion , which makes it $27.20 revenue per share.
Of the last four earnings reports from Johnson & Johnson, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.57 for the next earnings report. Johnson & Johnson’s next earnings report date is -.
The consensus rating of Wall Street analysts for Johnson & Johnson is Moderate Buy (2.06), with a target price of $186.33, which is +9.48% compared to the current price. The earnings rating for Johnson & Johnson stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Johnson & Johnson has a dividend yield of 2.59% with a dividend per share of $4.52 and a payout ratio of 61.00%.
Johnson & Johnson has a Sell technical analysis rating based on Technical Indicators (ADX : 9.82, ATR14 : 2.70, CCI20 : -128.81, Chaikin Money Flow : -0.01, MACD : -1.03, Money Flow Index : 43.32, ROC : 0.23, RSI : 48.51, STOCH (14,3) : 19.31, STOCH RSI : 0.00, UO : 47.00, Williams %R : -80.69), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Johnson & Johnson in the last 12-months were: Alex Gorsky (Option Excercise at a value of $30 325 274), Ashley McEvoy (Option Excercise at a value of $0), Jennifer L. Taubert (Option Excercise at a value of $0), Joaquin Duato (Option Excercise at a value of $11 037 462), Joseph J. Wolk (Option Excercise at a value of $0), Kathryn E. Wengel (Option Excercise at a value of $2 901 600), Kathryn E. Wengel (Sold 40 000 shares of value $6 920 039 ), Mathai Mammen (Option Excercise at a value of $0), Michael H. Ullmann (Option Excercise at a value of $0), Peter M. Fasolo (Option Excercise at a value of $0), Robert J. Decker (Option Excercise at a value of $1 339 234), Robert J. Decker (Sold 18 462 shares of value $3 216 740 ), Thibaut Mongon (Option Excercise at a value of $3 099 895), Thibaut Mongon (Sold 34 453 shares of value $6 072 408 ), Vanessa Broadhurst (Option Excercise at a value of $0), William Hait (Option Excercise at a value of $2 685 977), William Hait (Sold 29 599 shares of value $5 433 696 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total sales are generated in the United States.
CEO: Alex Gorsky
Telephone: +1 732 524-0400
Address: One Johnson and Johnson Plaza, New Brunswick 08933, NJ, US
Number of employees: 136 400
Wed, 20 Jul 2022 12:43 GMT Johnson & Johnson (JNJ) Receives a Hold from Atlantic Equities
- TipRanks. All rights reserved.Fri, 17 Jun 2022 03:47 GMT Why Johnson & Johnson Stock is Attractive Now
- TipRanks. All rights reserved.Thu, 21 Apr 2022 03:15 GMT Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and AbbVie (ABBV)
- TipRanks. All rights reserved.Thu, 21 Apr 2022 03:05 GMT Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Moderna (MRNA)
- TipRanks. All rights reserved.Fri, 15 Apr 2022 06:11 GMT All Eyes on Johnson & Johnson as it Reports Q1 Earnings
- TipRanks. All rights reserved.Wed, 02 Mar 2022 06:03 GMT Making Sense of Johnson & Johnsons Newly Added Risk Factors
- TipRanks. All rights reserved.Tue, 18 Jan 2022 05:26 GMT Johnson & Johnson Settles Opioid Case with New Mexico
- TipRanks. All rights reserved.Wed, 05 Jan 2022 16:30 GMT Johnson & Johnson: Concerning Growth, but Reliable Dividends
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.